Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Talalight

Retina Specialist Huntsville, AL Medical Doctor

NPI 1700094661 CMS profile 697033

2331 Whitesburg Dr S, Huntsville, AL 35801

Open in the dashboard

General payments

$3,718

127 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Talalight of Huntsville, AL is reported in the CMS Open Payments database as having received $3,718 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,001 34
2024 General $1,335 45
2023 General $585 29
2022 General $362 12
2021 General $48 3
2020 General $100 1
2019 General $287 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Talalight
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Alexander Talalight were reported at $1,001. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Alexander Talalight Retina Specialist median Middle half National median
2019 $287 $410 $157–$1,517 $163
2020 $100 $168 $65–$778 $114
2021 $48 $258 $101–$1,161 $132
2022 $362 $418 $162–$1,488 $149
2023 $585 $476 $178–$1,312 $160
2024 $1,335 $520 $188–$1,372 $164
2025 $1,001 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $897 39 payments
  2. Alexion Pharmaceuticals, Inc. $563 19 payments
  3. Regeneron Healthcare Solutions, Inc. $343 3 payments
  4. Genentech USA, Inc. $299 12 payments
  5. Apellis Pharmaceuticals, Inc. $234 6 payments
  6. UCB, Inc. $182 6 payments
  7. Astellas Pharma US Inc $170 8 payments
  8. Bausch & Lomb Americas Inc. $164 7 payments
  9. Allergan Inc. $146 1 payment
  10. Novartis Pharmaceuticals Corporation $141 2 payments
  11. Other $578 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,718 127 payments
Products named General payments · program years 2019–2025
  1. OZURDEX $678 29 payments
  2. ULTOMIRIS $468 15 payments
  3. VABYSMO $263 10 payments
  4. EYLEA $225 2 payments
  5. Syfovre $208 5 payments
  6. Rystiggo $153 5 payments
  7. XEN $146 1 payment
  8. DURYSTA $129 6 payments
  9. UPLIZNA $121 5 payments
  10. Izervay $120 6 payments
  11. Other $1,179 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

2,242

Median for Ophthalmology: 891

Drug cost

$48,919

Median for Ophthalmology: $68,233

Branded share of claims

19.2%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 248 $12,966
Timolol Maleate Generic 598 $6,920
Latanoprost Generic 582 $5,466
Loteprednol Etabonate Generic 18 $4,186
Brimonidine Tartrate Generic 60 $3,879
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 218 $3,866
Ofloxacin Generic 190 $3,144
Simbrinza Brinzolamide/Brimonidine Tart Brand 13 $2,710
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 12 $1,698
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 124 $1,429

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$1,635,268

Of which drugs: $1,224,958

Medicare patients

892

Average age 78

Services billed

17,440

533 women, 359 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 36%
Ischemic heart disease 35%
Chronic kidney disease 33%
Atrial fibrillation 21%
Osteoporosis 19%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 76 1,098 $711,968
Injection, faricimab-svoa, 0.1 mg J2777 Office 16 6,900 $185,317
Injection, pegcetacoplan, intravitreal, 1 mg J2781 Office 18 1,230 $143,769
Injection, avacincaptad pegol, 0.1 mg J2782 Office 16 1,120 $96,606
Injection, bevacizumab, 10 mg J9035 Office 219 1,211 $67,517

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $410
$410 — —
OZURDEX
  • AbbVie, Inc. $259
$259 — —
Rystiggo
  • UCB, Inc. $153
$153 — —
Syfovre
  • Apellis Pharmaceuticals, Inc. $151
$151 — 1,230
VABYSMO
  • Genentech USA, Inc. $82
$82 — 6,900

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Retina Specialist in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record